Table 1.
Cohort clinical characteristics
| Characteristic | ATV |
|---|---|
| Number of patients | 571 |
| ATV dose: | |
| 80 mg | 534 (93.5%) |
| 40 mg | 37 (6.5%) |
| Demographics: | |
| Male | 443 (77.6%) |
| Age, mean ± SD (years) | 63.5 ± 11.5 |
| Body mass index, median (IQR) (kg/m2) | 28.2 (25.2–31.4) |
| Smoking: | |
| Previous/never | 414 (72.5%) |
| Current | 157 (27.5%) |
| Comorbidities: | |
| Hypertension | 314 (55.0%) |
| Hyperlipidaemia prior to index NSTE‐ACS | 295 (51.7%) |
| Diabetes mellitus | 102 (17.9%) |
| CKD (Cr > 150 μmol/L) | 32 (5.6%) |
| Prior CVD (previous MI, stroke, TIA or PAD) | 168 (29.4%) |
| Hepatic disease | 5 (0.9%) |
| Drugs at visit 2: | |
| Aspirin | 539 (94.4%) |
| P2Y12 inhibitor | 486 (85.1%) |
| Beta‐blocker | 488 (85.5%) |
| ACEI/ARB | 481 (84.2%) |
| Loop diuretic | 96 (16.8%) |
| Thiazide diuretic | 19 (3.3%) |
| Amiodarone | 7 (1.2%) |
| Proton pump inhibitor | 229 (40.1%) |
| CYP3A inducer | 3 (0.5%) |
| Moderate/strong CYP3A inhibitor | 21 (3.7%) |
| Blood sample characteristics: | |
| Sample storage duration, median (IQR) (y) | 5.9 (5.3–7.4) |
| Time since last ATV, median (IQR) (h) | 13.4 (12.5–15.8) |
ACEI/ARB, angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker; ATV, atorvastatin; CKD, chronic kidney disease; CVD, cardiovascular disease; IQR, interquartile range; MI, myocardial infarction; NSTE‐ACS, non‐ST elevation acute coronary syndrome; PAD, peripheral artery disease; SD, standard deviation; TIA, transient ischaemic attack.